Wait Until Meme Stock Wave Passes Before Buying Clover Health

47
18
Favorite

Wait Until Meme Stock Wave Passes Before Buying Clover Health

InvestorPlace2021-06-17

A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved It’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（18）

Phyusin
·2021-06-22
Should I hold?
Reply
Like
Report
SoonChai
·2021-06-18
KIV
Reply
Like
Report
SoonChai
·2021-06-18
KIV
Reply
Like
Report
Toodles
·2021-06-18
This write up didn't bother mentioning how hindenburg research release hit pieces to bring it down. The depressed price wasn't because ppl lost interest, but its artificially kept down with an insanely high short interest. Intentionally left out these info.
Reply
2
Report
daniao
·2021-06-18
Why you like that.
Reply
1
Report
Champion365
·2021-06-17
Disappointed
Reply
2
Report
Veldora
·2021-06-17
Why it sound like hedge, especially the short expired tomorrow.
Reply
1
Report
Lionel83
·2021-06-17
Nice one but in end is about people beliefs ratherthan fundamentals of the company, that matters
Reply
1
Report
Fold Replies
- Veldora:
  This article sound like hedge. they have growth so long term investor wont even bother votality
  2021-06-17
  Reply
  Report
Raymondsj
·2021-06-17
Lkxhsnjas
Reply
Like
Report
LINXIAOYUAN
·2021-06-17
Bbnn
Reply
Like
Report
daberukk
·2021-06-17
good read!
Reply
1
Report
Eagle8
·2021-06-17
Happy hunting....as per Buffet, buy when everyone is selling and sell when everyone is buying + Fundamentals & do your homework.
Reply
1
Report
EKT
·2021-06-17
?
Reply
1
Report
Mastakilla25
·2021-06-17
Nice
Reply
1
Report
Fold Replies
- Mastakilla25:
  ?
  2021-06-17
  Reply
  Report
- 4ebeaef4:
  Pls reply to me
  2021-06-17
  Reply
  Report
EfraChan
·2021-06-17
Post
Reply
1
Report
Pyscho
·2021-06-17
Bad stock
Reply
6
Report
Fold Replies
- Pyscho:
  good
  2021-06-29
  Reply
  Report
- joeycze:
  reply ty
  2021-06-17
  Reply
  Report
- Zhaoxiang:
  yup
  2021-06-17
  Reply
  Report
View more 2 comments
HoldTheDoor
·2021-06-17
Okie
Reply
3
Report
Fold Replies
- Zhaoxiang:
  ty
  2021-06-17
  Reply
  Report
- 88_TWB_88:
  comment & like thks
  2021-06-17
  Reply
  Report
Chokupoo88
·2021-06-17
Good
Reply
2
Report
Fold Replies
- 88_TWB_88:
  comment & like thks
  2021-06-17
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1166743946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-17 10:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166743946","market":"us","top_or_hot":-1,"title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","media":"InvestorPlace","content":"<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLOV","symbol_name":"Clover Health Corp","start_time":0,"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","article_id":"1166743946","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","pubTimestamp":1623898222,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLOV":"Clover Health Corp"},"translate_title":"等到Meme股浪过去再买Clover Health","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLOV":0.9},"content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":120867542,"gmtCreate":1624319265686,"gmtModify":1703833200997,"author":{"id":"3584490239949882","authorId":"3584490239949882","name":"Phyusin","avatar":"https://static.tigerbbs.com/73d7e61a3a910d1d25acb7dcee29f7ca","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Should I hold?","listText":"Should I hold?","text":"Should I hold?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120867542","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":166300278,"gmtCreate":1623990206094,"gmtModify":1703825891819,"author":{"id":"3581934472556457","authorId":"3581934472556457","name":"SoonChai","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"KIV","listText":"KIV","text":"KIV","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166300278","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":166977800,"gmtCreate":1623990181300,"gmtModify":1703825890510,"author":{"id":"3581934472556457","authorId":"3581934472556457","name":"SoonChai","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"KIV","listText":"KIV","text":"KIV","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166977800","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168105600,"gmtCreate":1623957751900,"gmtModify":1703824651232,"author":{"id":"3575039460234674","authorId":"3575039460234674","name":"Toodles","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"This write up didn't bother mentioning how hindenburg research release hit pieces to bring it down. The depressed price wasn't because ppl lost interest, but its artificially kept down with an insanely high short interest. Intentionally left out these info.&nbsp;","listText":"This write up didn't bother mentioning how hindenburg research release hit pieces to bring it down. The depressed price wasn't because ppl lost interest, but its artificially kept down with an insanely high short interest. Intentionally left out these info.&nbsp;","text":"This write up didn't bother mentioning how hindenburg research release hit pieces to bring it down. The depressed price wasn't because ppl lost interest, but its artificially kept down with an insanely high short interest. Intentionally left out these info.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168105600","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168941130,"gmtCreate":1623947942120,"gmtModify":1703824478596,"author":{"id":"3575541782223727","authorId":"3575541782223727","name":"daniao","avatar":"https://static.tigerbbs.com/f1193bc7847be1da820c2d94723471b2","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Why you like that.&nbsp;","listText":"Why you like that.&nbsp;","text":"Why you like that.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168941130","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161195034,"gmtCreate":1623909222928,"gmtModify":1703823274437,"author":{"id":"3573653602271971","authorId":"3573653602271971","name":"Champion365","avatar":"https://static.tigerbbs.com/04df800589718231e24e96f7a0b551cc","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Disappointed","listText":"Disappointed","text":"Disappointed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161195034","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161199557,"gmtCreate":1623908746879,"gmtModify":1703823266984,"author":{"id":"3580473686930895","authorId":"3580473686930895","name":"Veldora","avatar":"https://static.tigerbbs.com/2c60768e017f3418615cd7dea3a291ec","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Why it sound like hedge, especially the short expired tomorrow.","listText":"Why it sound like hedge, especially the short expired tomorrow.","text":"Why it sound like hedge, especially the short expired tomorrow.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161199557","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161358674,"gmtCreate":1623906637398,"gmtModify":1703823213586,"author":{"id":"3580018421939608","authorId":"3580018421939608","name":"Lionel83","avatar":"https://static.tigerbbs.com/3db428a23c73ce1d9ebd4b7b27e8ddbb","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"Nice one but in end is about people beliefs ratherthan fundamentals of the company, that matters","listText":"Nice one but in end is about people beliefs ratherthan fundamentals of the company, that matters","text":"Nice one but in end is about people beliefs ratherthan fundamentals of the company, that matters","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161358674","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4834237,"gmtCreate":1623908828113,"gmtModify":1663229135336,"authorId":3580473686930895,"author":{"id":3580473686930895,"authorId":3580473686930895,"name":"Veldora","avatar":"https://static.tigerbbs.com/2c60768e017f3418615cd7dea3a291ec","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161358674,"type":1,"supId":0,"prevId":0,"content":"This article sound like hedge. they have growth so long term investor wont even bother votality ","text":"This article sound like hedge. they have growth so long term investor wont even bother votality ","html":"This article sound like hedge. they have growth so long term investor wont even bother votality "}],"langContent":"EN"},{"id":161330028,"gmtCreate":1623904150964,"gmtModify":1703823136204,"author":{"id":"3569352578277592","authorId":"3569352578277592","name":"Raymondsj","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Lkxhsnjas","listText":"Lkxhsnjas","text":"Lkxhsnjas","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161330028","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161974424,"gmtCreate":1623903252368,"gmtModify":1703823106213,"author":{"id":"3585208784622595","authorId":"3585208784622595","name":"LINXIAOYUAN","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Bbnn","listText":"Bbnn","text":"Bbnn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161974424","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161923806,"gmtCreate":1623901554405,"gmtModify":1703823053393,"author":{"id":"3574812182510750","authorId":"3574812182510750","name":"daberukk","avatar":"https://static.tigerbbs.com/125530ebf668f660df11ec2044b52a98","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"good read!","listText":"good read!","text":"good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161923806","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161983377,"gmtCreate":1623900537199,"gmtModify":1703823027454,"author":{"id":"3586237326361443","authorId":"3586237326361443","name":"Eagle8","avatar":"https://community-static.tradeup.com/news/f3c34936358021d83ba115bba6f89408","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Happy hunting....as per Buffet, buy when everyone is selling and sell when everyone is buying + Fundamentals &amp; do your homework.","listText":"Happy hunting....as per Buffet, buy when everyone is selling and sell when everyone is buying + Fundamentals &amp; do your homework.","text":"Happy hunting....as per Buffet, buy when everyone is selling and sell when everyone is buying + Fundamentals & do your homework.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161983377","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161932774,"gmtCreate":1623899869998,"gmtModify":1703823006688,"author":{"id":"3569624208133637","authorId":"3569624208133637","name":"EKT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161932774","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161993896,"gmtCreate":1623899207215,"gmtModify":1703822986450,"author":{"id":"3582063999704102","authorId":"3582063999704102","name":"Mastakilla25","avatar":"https://static.tigerbbs.com/77f564e901f5c843cd5dd978201a5a34","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/161993896","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4831498,"gmtCreate":1623899395769,"gmtModify":1663229123935,"authorId":3582063999704102,"author":{"id":3582063999704102,"authorId":3582063999704102,"name":"Mastakilla25","avatar":"https://static.tigerbbs.com/77f564e901f5c843cd5dd978201a5a34","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161993896,"type":1,"supId":4831449,"prevId":0,"content":"?","text":"?","html":"?"},{"id":4831449,"gmtCreate":1623899237430,"gmtModify":1663229123540,"authorId":3575777532787835,"author":{"id":3575777532787835,"authorId":3575777532787835,"name":"4ebeaef4","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161993896,"type":1,"supId":0,"prevId":0,"content":"Pls reply to me","text":"Pls reply to me","html":"Pls reply to me"}],"langContent":"EN"},{"id":161993381,"gmtCreate":1623899203643,"gmtModify":1703822985967,"author":{"id":"3581930297199023","authorId":"3581930297199023","name":"EfraChan","avatar":"https://static.tigerbbs.com/fbe91d507b4ebaf56e62150f45033cf5","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Post","listText":"Post","text":"Post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161993381","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161901002,"gmtCreate":1623898778306,"gmtModify":1703822975425,"author":{"id":"3575544483678715","authorId":"3575544483678715","name":"Pyscho","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Bad stock","listText":"Bad stock","text":"Bad stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/161901002","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5063475,"gmtCreate":1624937559248,"gmtModify":1663230250754,"authorId":3575544483678715,"author":{"id":3575544483678715,"authorId":3575544483678715,"name":"Pyscho","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161901002,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"},{"id":4831874,"gmtCreate":1623900439567,"gmtModify":1663229124933,"authorId":3575243444886570,"author":{"id":3575243444886570,"authorId":3575243444886570,"name":"joeycze","avatar":"https://community-static.tradeup.com/news/10ea87af1aa97f08dd1231d3fc85cc24","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161901002,"type":1,"supId":0,"prevId":0,"content":"reply ty","text":"reply ty","html":"reply ty"},{"id":4831692,"gmtCreate":1623899955758,"gmtModify":1663229124244,"authorId":3573361937273706,"author":{"id":3573361937273706,"authorId":3573361937273706,"name":"Zhaoxiang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161901002,"type":1,"supId":4831421,"prevId":0,"content":"yup","text":"yup","html":"yup"},{"id":4831366,"gmtCreate":1623898990521,"gmtModify":1663229122736,"authorId":3582503329600891,"author":{"id":3582503329600891,"authorId":3582503329600891,"name":"88_TWB_88","avatar":"https://static.tigerbbs.com/00cb7ae6d4c8f5f282b6f3a594a2c648","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161901002,"type":1,"supId":0,"prevId":0,"content":"comment &amp; like thks","text":"comment &amp; like thks","html":"comment &amp; like thks"},{"id":4831421,"gmtCreate":1623899162364,"gmtModify":1663229122133,"authorId":3581930297199023,"author":{"id":3581930297199023,"authorId":3581930297199023,"name":"EfraChan","avatar":"https://static.tigerbbs.com/fbe91d507b4ebaf56e62150f45033cf5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161901002,"type":1,"supId":0,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"}],"langContent":"EN"},{"id":161903588,"gmtCreate":1623898760744,"gmtModify":1703822977367,"author":{"id":"3580469278772937","authorId":"3580469278772937","name":"HoldTheDoor","avatar":"https://static.tigerbbs.com/635db0f1af7cd6ef4ce184b75309a7b0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Okie","listText":"Okie","text":"Okie","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/161903588","repostId":1166743946,"repostType":4,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4831693,"gmtCreate":1623899962535,"gmtModify":1663229125438,"authorId":3573361937273706,"author":{"id":3573361937273706,"authorId":3573361937273706,"name":"Zhaoxiang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161903588,"type":1,"supId":4831373,"prevId":0,"content":"ty","text":"ty","html":"ty"},{"id":4831373,"gmtCreate":1623898999040,"gmtModify":1663229121749,"authorId":3582503329600891,"author":{"id":3582503329600891,"authorId":3582503329600891,"name":"88_TWB_88","avatar":"https://static.tigerbbs.com/00cb7ae6d4c8f5f282b6f3a594a2c648","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161903588,"type":1,"supId":0,"prevId":0,"content":"comment &amp; like thks","text":"comment &amp; like thks","html":"comment &amp; like thks"}],"langContent":"EN"},{"id":161077654,"gmtCreate":1623898651078,"gmtModify":1703822968723,"author":{"id":"3583997622779762","authorId":"3583997622779762","name":"Chokupoo88","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161077654","repostId":1166743946,"repostType":2,"repost":{"id":"1166743946","pubTimestamp":1623898222,"share":"https://www.laohu8.com/m/news/1166743946?lang=&edition=full","pubTime":"2021-06-17 10:50","market":"us","language":"en","title":"Wait Until Meme Stock Wave Passes Before Buying Clover Health","url":"https://stock-news.laohu8.com/highlight/detail?id=1166743946","media":"InvestorPlace","summary":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to c","content":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer&nbsp;Clover Health&nbsp;(NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its&nbsp;plans to go public via a merger&nbsp;with special purpose acquisition company (SPAC)&nbsp;Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after&nbsp;Hindenburg Research&nbsp;suggested that Clover Health had used questionable tactics to&nbsp;lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n<ul>\n <li>Low-priced stock</li>\n <li>High short interest</li>\n <li>Float isn’t too large</li>\n <li>Not a blue-chip stock</li>\n <li>Company has underdog status</li>\n</ul>\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts&nbsp;downgraded their rating on&nbsp;Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n<blockquote>\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n</blockquote>\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wait Until Meme Stock Wave Passes Before Buying Clover Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWait Until Meme Stock Wave Passes Before Buying Clover Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nA recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the...\n\n<a href=\"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/06/wait-until-meme-stock-wave-passes-before-buying-clov-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166743946","content_text":"A recent big-bank analyst's downgrade of CLOV stock underscores the risks involved\nIt’s amazing to consider that next-generation Medicare Advantage insurer Clover Health (NASDAQ:CLOV) would become the focus of so much attention. CLOV stock was completely under the radar not too long ago, but things can change quickly in this fast-paced market.\nAs you may recall, Clover Health announced its plans to go public via a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings III.\nThat company traded as IPOC stock, but that’s gone now and we have CLOV stock in its place. It was an attention-grabbing event because Social Capital Hedosophia Holdings III was sponsored by none other than Chamath Palihapitiya (a.k.a., the SPAC Lord).\nSo much has happened since then. From hype-tastic debut to SPAC-tacular failure – and now the meme target du jour – there’s an awful lot to unpack here. Ready to take a roller coaster ride?\nA Closer Look at CLOV Stock\nPrior to the aforementioned reverse merger announcement in October 2020, CLOV/IPOC stock stayed close to the $10 level.\nHowever, that announcement gave the stock a jolt, and it finished the year at nearly $17.\nSPAC mania faded somewhat in early 2021, and so did the Clover Health share price. In May, the stock bottomed out near $7.\nThat’s mind-blowing, if you think about it. The post-merger disappointment was so severe that CLOV stock dropped below the pre-merger-announcement price.\nCome to think of it, I probably should have reserved the term “mind-blowing” for what happened next.\nWith hardly any warning, the Clover Health share price shot up like a rocket, reaching a 52-week high of $28.85 on June 9.\nThat moon shot was clearly unsustainable, as CLOV stock soon retraced nearly half of that move. As of June 11, it was trading at $15.03.\nCredit Reddit\nSo, what the heck happened in June? Was there some spectacular news development involving Clover Health? A game-changing innovation, or perhaps a blockbuster earnings report?\nThe answer is: none of the above. Like it or not, we must credit Reddit for the wild pop in CLOV stock.\nThe irony runs deep here. In January, the stock tanked after Hindenburg Research suggested that Clover Health had used questionable tactics to lure retail investors into purchasing the company’s shares.\nAnd now, there’s no need to lure people into the trade as they’re gladly jumping in, often without conducting the proper due diligence.\nMaybe we all should have seen this coming. After all, CLOV stock checked all of the right boxes for a Reddit short-squeeze target:\n\nLow-priced stock\nHigh short interest\nFloat isn’t too large\nNot a blue-chip stock\nCompany has underdog status\n\nA Devastating Downgrade\nI have to admit, I like the idea of betting on an underdog. Still, I believe it’s wise to wait until the volatility passes before taking a position.\nMoreover, we might expect the analyst community to issue downgrades on CLOV stock. In fact, one big-bank analyst has already weighed in with a not-too-optimistic outlook.\nRecently, Bank of America analysts downgraded their rating on Clover Health from “neutral” (which is similar to “hold”) to “underperform” (similar to “sell”).\nOn top of that, they assigned a $10 price target to CLOV stock. That’s pretty devastating, as it implies a 33% haircut if the stock is trading at around $15.\nBank of America analyst Kevin Fischbeck cited comparative valuation concerns:\n\n “After the recent spike in CLOV, we are downgrading [because] the company is now trading at a 70% premium to ALHC [its closest comparable stock] despite a similar growth profile and lower near term margin trajectory.”\n\nThe Bottom Line\nFischbeck’s point is well taken. The current price of Clover Health shares isn’t necessarily justified by the company’s fiscal standing.\nAnd beyond that, there’s nothing wrong with sitting on the sidelines and enjoying the fireworks from afar – which also means avoiding any potential injuries.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4831362,"gmtCreate":1623898983693,"gmtModify":1663229122649,"authorId":3582503329600891,"author":{"id":3582503329600891,"authorId":3582503329600891,"name":"88_TWB_88","avatar":"https://static.tigerbbs.com/00cb7ae6d4c8f5f282b6f3a594a2c648","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161077654,"type":1,"supId":0,"prevId":0,"content":"comment &amp; like thks","text":"comment &amp; like thks","html":"comment &amp; like thks"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":47,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}